Acrux Narrows FY26 Loss 90% as Female Testosterone Development Gains Momentum

Financial Results Highlight Revenue Growth and Loss Reduction

Acrux Limited (ASX:ACR) posted a 46% jump in revenue to $6.596 million for the year ended 30 June 2026, powered by a surge in profit share and royalty income from its US topical generic products and milestone payments from licensing agreements. Despite this, the company remained in the red with a net loss after tax of $604,000, a marked 90% improvement from the prior year’s $5.945 million loss.

Operational cash flows swung positive to $1.019 million, supporting a cash balance of $1.705 million at year-end, bolstered by a $1.6 million institutional placement and R&D tax incentive receipts. Acrux also divested a low-performing generic cream, adding USD 0.55 million in cash proceeds.

Strategic Pivot to Female Testosterone Therapy

FY26 marked a strategic inflection point as Acrux shifted focus from crowded topical generics to developing a proprietary Female Testosterone Metered Dose Transdermal System (MDTS). This product targets Hypoactive Sexual Desire Disorder (HSDD), a condition affecting an estimated 10% of adult women and 4.9 million menopausal women in the US alone.

The company’s MDTS leverages Acrux’s “patchless patch” technology, designed for accurate, controlled transdermal delivery of testosterone tailored specifically for women, aiming to overcome dosing and transfer issues seen with off-label male testosterone products.

Encouraging Phase II clinical results demonstrated statistically significant improvements in sexual function at the selected 90 μL dose, laying a clinical foundation for the planned Phase III trials. Acrux has engaged regulators including the US FDA and Australia’s TGA, receiving constructive feedback that clarifies the regulatory pathway, including potential reliance on a 505(b)(2) submission in the US and a literature-based approach in Australia.

Partnerships and Commercialisation Plans Underway

Acrux is actively pursuing co-development and commercialisation partnerships with established players in women’s health. The model envisages Acrux contributing its formulation, device, and regulatory expertise, while partners provide clinical development, manufacturing, and commercial capabilities. The company reports strong interest from potential partners, now conducting due diligence.

Meanwhile, Acrux continues to monetise its existing generic portfolio, including licensing deals such as the amended agreement with Gedeon Richter Plc for the Estradiol spray Lenzetto® in Australia, which triggered an upfront milestone of $1.35 million and could deliver up to $5.4 million in future payments.

Cost Management and Governance Focus

Operational expenditure declined year-on-year, reflecting a deliberate realignment of resources towards female testosterone development and the cessation of low-potential generic pipeline projects. Further cost savings are expected in FY27 through headcount reductions and overhead rationalisation.

Governance remains robust with a stable Board and senior management team, including CEO John Warmbrunn, who joined in mid-2025. The company maintains a comprehensive ESG framework emphasising environmental sustainability, social responsibility, and ethical corporate governance.

Going Concern and Future Outlook

The company’s financial statements note a material uncertainty regarding going concern, contingent on successful revenue generation, milestone receipts, and securing a co-development partner for Phase III trials. Acrux’s management remains confident in its cash flow projections and funding strategies, including continued eligibility for R&D tax incentives and the ability to manage expenditure.

Looking ahead, Acrux aims to finalise partnership agreements, advance regulatory and manufacturing preparations, and initiate pivotal Phase III clinical trials for its Female Testosterone MDTS. The company is also exploring potential applications beyond HSDD, including premature menopause and post-cancer sexual dysfunction, though these remain subject to further research and approval.

This strategic pivot places Acrux at the forefront of a growing women’s health market, but the path to commercialisation carries typical biotech uncertainties around clinical outcomes, regulatory approvals, and partnership execution.